Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06842134 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E
A Phase 1 study, sponsored by Baxter Healthcare Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06842134: Completed Phase 1 study, sponsored by Baxter Healthcare Corporation.
NCT06842134 is a Phase 1 study that has completed, run by Baxter Healthcare Corporation. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06842134, a Phase 1 study, has completed, sponsored by Baxter Healthcare Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a phase 1, prospective, single-center, randomized sequence, open label, 2-way crossover study comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E. It is planned to randomize approximately 16 healthy male and female subjects. All study periods will be completed during a single residency, the overall duration of residency will be 11 days (10 nights).
Primary Outcome
Serum PK parameter
Interventions
- DRUG Numeta G16%E
- DRUG Sodium Glycerophosphate Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2025-05-22 |
| Phase | Phase 1 |
What the finished NCT06842134 record still lists
NCT06842134 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Numeta G16%E is the first listed.
NCT06842134 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06842134 about?
NCT06842134 is a clinical study titled "A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E". This is a phase 1, prospective, single-center, randomized sequence, open label, 2-way crossover study comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E. It is planned to randomize approximately 16 healthy male and female subjects. All study periods will be completed du...
What is the current status of trial NCT06842134?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-01-27. Estimated completion is 2025-05-22.
What interventions are being tested in trial NCT06842134?
The interventions under investigation include: Numeta G16%E (DRUG), Sodium Glycerophosphate Injection (DRUG).
Who is sponsoring clinical trial NCT06842134?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06842134's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI